Genética y Clínica de las Neoplasias Hematológicas y el Trasplante Hematopoyético

Los-Arcos, I; Iacoboni, G; Aguilar-Guisado, M; Alsina-Manrique, L; de Heredia, CD; Fortuny-Guasch, C; Garcia-Cadenas, I; Garcia-Vidal, C; Gonzalez-Vicent, M; Hernani, R; Kwon, M; Machado, M; Martinez-Gomez, X; Maldonado, VO; Pla, CP; Pinana, JL; Pomar, V; Reguera-Ortega, JL; Salavert, M; Soler-Palacin, P; Vazquez-Lopez, L; Barba, P; Ruiz-Camps, I.

Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper

INFECTION. 2021; 49(2): 215-231 Nº de citas: 109 [doi:10.1007/s15010-020-01521-5]

Melgarejo-Ortuno, A; Escudero-Vilaplana, V; Revuelta, JL; Bailen, R; Collado-Borrell, R; Gomez-Centurion, I; Oarbeascoa, G; Kwon, M; Heranz, A; Diez-Martin, JL; Sanjurjo, M.

Tocilizumab as salvage treatment of refractory pulmonary acute graft-versus-host disease

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2021; 27(3): 751-755 Nº de citas: 7 [doi:10.1177/1078155220948934]

Domingo-Gonzalez, A; Osorio, S; Landete, E; Monsalvo, S; Diez-Martin, JL.

A second administration of glucarpidase in a different cycle of high-dose methotrexate: Is it safe and effective in adults?

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2021; 27(3): 734-738 Nº de citas: 4 [doi:10.1177/1078155220946464]

Suarez-Gonzalez, J; Seidel, V; Andres-Zayas, C; Izquierdo, E; Buno, I.

Novel biallelic variant in BBS9 causative of Bardet-Biedl syndrome: expanding the spectrum of disease-causing genetic alterations

BMC MEDICAL GENOMICS. 2021; 14(1): 91-91 Nº de citas: 6 [doi:10.1186/s12920-021-00943-w]

Muniz, P; Kwon, M; Carbonell, D; Chicano, M; Bailen, R; Oarbeascoa, G; Suarez-Gonzalez, J; Andres-Zayas, C; Menarguez, J; Dorado, N; Gomez-Centurion, I; Anguita, J; Diez-Martin, JL; Martinez-Laperche, C; Buno, I.

Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide

Frontiers in Immunology. 2021; 12: 642087-642087 Nº de citas: 7 [doi:10.3389/fimmu.2021.642087]

Regalado-Artamendi, I; Jimenez-Ubieto, A; Hernandez-Rivas, JA; Navarro, B; Nunez, L; Alaez, C; Cordoba, R; Penalver, FJ; Cannata, J; Estival, P; Quiroz-Cervantes, K; Grau, RR; Velasco, A; Martos, R; Domingo-Gonzalez, A; Benito-Parra, L; Gomez-Sanz, E; Lopez-Jimenez, J; Matilla, A; Herraez, MR; Penalva, MJ; Garcia-Suarez, J; Diez-Martin, JL; Bastos-Oreiro, M.

Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study

Hemasphere. 2021; 5(3): Nº de citas: 49 [doi:10.1097/HS9.0000000000000538]

Benitez-Carabante, MI; Belendez, C; Gonzalez-Vicent, M; Alonso, L; Uria-Oficialdegui, ML; Torrent, M; Perez-Hurtado, JM; Fuster, JL; Cela, E; Diaz-de-Heredia, C; Grp Espanol Trasplante.

Matched sibling donor stem cell transplantation for sickle cell disease: Results from the Spanish group for bone marrow transplantation in children

EUROPEAN JOURNAL OF HAEMATOLOGY. 2021; 106(3): 408-416 Nº de citas: 6 [doi:10.1111/ejh.13566]

Solan, L; Carbonell, D; Muniz, P; Dorado, N; Landete, E; Chicano-Lavilla, M; Anguita, J; Gayoso, J; Kwon, M; Diez-Martin, JL; Martinez-Laperche, C; Buno, I.

Elafin as a Predictive Biomarker of Acute Skin Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide

Frontiers in Immunology. 2021; 12: 516078-516078 Nº de citas: 10 [doi:10.3389/fimmu.2021.516078]

Vega-Garcia, N; Perez-Jaume, S; Esperanza-Cebollada, E; Vicente-Garces, C; Torrebadell, M; Jimenez-Velasco, A; Ortega, M; Llop, M; Abad, L; Vagace, JM; Minguela, A; Pratcorona, M; Sanchez-Garcia, J; Garcia-Calderon, CB; Gomez-Casares, MT; Martin-Clavero, E; Escudero, A; Martinez-Gallo, MR; Munoz, L; Velasco, MR; Garcia-Morin, M; Catala, A; Pascual, A; Velasco, P; Fernandez, JM; Lassaletta, A; Fuster, JL; Badell, I; Molinos-Quintana, A; Molines, A; Guerra-Garcia, P; Perez-Martinez, A; Garcia-Abos, M; Ortiz, RR; Pisa, S; Adan, R; de Heredia, CD; Dapena, JL; Rives, S; Ramirez-Orellana, M; Camos, M; Spanish Soc Paediat Haematology On.

Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment

Frontiers In Pediatrics. 2021; 8: 614521-614521 Nº de citas: 6 [doi:10.3389/fped.2020.614521]

Barbui, T; De Stefano, V; Alvarez-Larran, A; Iurlo, A; Masciulli, A; Carobbio, A; Ghirardi, A; Ferrari, A; Cancelli, V; Elli, EM; Andrade-Campos, MM; Kabat, MG; Kiladjian, JJ; Palandri, F; Benevolo, G; Garcia-Gutierrez, V; Fox, ML; Foncillas, MA; Morcillo, CM; Rumi, E; Osorio, S; Papadopoulos, P; Bonifacio, M; Cervantes, KSQ; Serrano, MS; Carreno-Tarragona, G; Sobas, MA; Lunghi, F; Patriarca, A; Elorza, BN; Angona, A; Mazo, EM; Koschmieder, S; Carli, G; Cuevas, B; Hernandez-Boluda, JC; Abadia, EL; Cirici, BX; Guglielmelli, P; Garrote, M; Cattaneo, D; Daffini, R; Cavalca, F; Bellosillo, B; Benajiba, L; Curto-Garcia, N; Bellini, M; Betti, S; Harrison, C; Rambaldi, A; Vannucchi, AM.

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

Blood Cancer Journal. 2021; 11(2): 21-21 Nº de citas: 27 [doi:10.1038/s41408-021-00417-3]

Dholaria, B; Labopin, M; Angelucci, E; Tischer, J; Arat, M; Ciceri, F; Gulbas, Z; Ozdogu, H; Sica, S; Diez-Martin, JL; Koc, Y; Pavlu, J; Socie, G; Giebel, S; Savani, BN; Nagler, A; Mohty, M.

Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia

Transplantation And Cellular Therapy. 2021; 27(2): Nº de citas: 10 [doi:10.1016/j.jtct.2020.10.008]

Sancho, JM; Fernandez-Alvarez, R; Gual-Capllonch, F; Gonzalez-Garcia, E; Grande, C; Gutierrez, N; Penarrubia, MJ; Batlle-Lopez, A; Gonzalez-Barca, E; Guinea, JM; Gimeno, E; Penalver, FJ; Fuertes, M; Bastos, M; Hernandez-Rivas, JA; Moraleda, JM; Garcia, O; Sorigue, M; Martin, A.

R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients >= 60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

Cancer Medicine. 2021; 10(4): 1314-1326 Nº de citas: 24 [doi:10.1002/cam4.3730]

Barbui, T; Vannucchi, AM; Alvarez-Larran, A; Iurlo, A; Masciulli, A; Carobbio, A; Ghirardi, A; Ferrari, A; Rossi, G; Elli, E; Andrade-Campos, MM; Kabat, MG; Kiladjian, JJ; Palandri, F; Benevolo, G; Garcia-Gutierrez, V; Fox, ML; Foncillas, MA; Morcillo, CM; Rumi, E; Osorio, S; Papadopoulos, P; Bonifacio, M; Cervantes, KSQ; Serrano, MS; Carreno-Tarragona, G; Sobas, MA; Lunghi, F; Patriarca, A; Elorza, BN; Angona, A; Mazo, EM; Koschmieder, S; Ruggeri, M; Cuevas, B; Hernandez-Boluda, JC; Abadia, EL; Cirici, BX; Guglielmelli, P; Garrote, M; Cattaneo, D; Daffini, R; Cavalca, F; Bellosillo, B; Benajiba, L; Curto-Garcia, N; Bellini, M; Betti, S; De Stefano, V; Harrison, C; Rambaldi, A.

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

LEUKEMIA. 2021; 35(2): 485-493 Nº de citas: 70 [doi:10.1038/s41375-020-01107-y]

Bailen, R; Kwon, M; Pascual-Cascon, MJ; Ferra, C; Sanz, J; Gallardo-Morillo, A; Garcia-Sola, A; Torrent, A; Jimenez-Lorenzo, MJ; Pinana, JL; Montoro, J; Oarbeascoa, G; Dorado, N; Gomez-Centurion, I; Munoz, C; Martinez-Laperche, C; Anguita, J; Buno, I; Diez-Martin, JL; Grp Espanol Trasplante Hematopoyet.

Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation

ANNALS OF HEMATOLOGY. 2021; 100(2): 541-553 Nº de citas: 34 [doi:10.1007/s00277-020-04317-7]

Mendez, M; Moreno-Carralero, MI; Peri, VL; Camacho-Galan, R; Bosch-Benitez, JM; Huerta-Aragones, J; Sanchez-Calero-Guilarte, J; Moreno-Risco, MB; Alonso-Dominguez, JM; Moran-Jimenez, MJ.

Congenital dyserythropoietic anemia types Ib, II, and III: novel variants in the CDIN1 gene and functional study of a novel variant in the KIF23 gene

ANNALS OF HEMATOLOGY. 2021; 100(2): 353-364 Nº de citas: 7 [doi:10.1007/s00277-020-04319-5]

Giebel, S; Labopin, M; Sobczyk-Kruszelnicka, M; Stelljes, M; Byrne, JL; Fegueux, N; Beelen, DW; Rovira, M; Spyridonidis, A; Blaise, D; Bornhauser, M; Karadogan, I; Savani, BN; Nagler, A; Mohty, M; Martin, S; Chevallier, P; Neubauer, A; Damaj, G; Koc, Y; Ganser, A; Collin, M; Yakoub-Agha, I; Ozdogu, H; Araujo, MC; Itala-Remes, M; Orchard, K; Isaksson, C; Bethge, W; Martin, H; Aljurf, M; Faber, E; Caballero, D; Zak, P; Leleu, X; Bay, JO; Rohrlich, PS; Kroger, N; Huynh, A; Schafer-Eckart, K; Milpied, N; Lenhoff, S; Ho, A; Lopez, JLB; Mordini, N; Lioure, B; Halaburda, K; Olivieri, A; Gedde-Dahl, T; Protheroe, R; Tischer, J; Klammer, M; Clausen, J; Potter, V; Ladetto, M; Tilly, H; Deconinck, E; Brecht, A; Muller, LP; Heinicke, T; Carrete, JPT; Bazarbachi, A; Remenyi, P; Rubio, MT; Fanin, R; Perez-Simon, JA; Niels, M; Diez-Martin, JL; Arat, M; Hermine, O; Socie, G; Cornelissen, JJ; Santarone, S; Guyotat, D; Bulabois, CE; Bernasconi, P; Johansson, JE; Vrhovac, R; Greinix, H; Lorenzo, JLL; Apte, S; Craddock, C; Kobbe, G; Zahrani, MA; Dreger, P; Lange, A; Tbakhi, A; Meijer, E; Llamas, CV; Santasusana, JMR; Corradini, P; Benedetti, F; Rambaldi, A; Gandemer, V; Malfuson, JV; Kaare, A; Risitano, A; Petrini, M; Selleri, C; Wu, DP; Principal Investigators Contr.

Total body irradiation plus fludarabine compared to busulfan plus fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

BONE MARROW TRANSPLANTATION. 2021; 56(2): 481-491 Nº de citas: 10 [doi:10.1038/s41409-020-01050-7]

Gonzalez, MJ; Urizar, E; Urtaran-Laresgoiti, M; Nuno-Solinis, R; Lazaro-Perez, E; Vazquez, L; Pascual-Cascon, MJ; Solano, C; Kwon, M; Gallego, C; Fernandez-Aviles, F.

Hospital and outpatient models for Hematopoietic Stem Cell Transplantation: A systematic review of comparative studies for health outcomes, experience of care and costs

PLoS One. 2021; 16(8): Nº de citas: 10 [doi:10.1371/journal.pone.0254135]

Mareque, M; Montesinos, P; Font, P; Guinea, JM; de la Fuente, A; Soto, J; Oyaguez, I; Brockbank, J; Iglesias, T; Llinares, J; Sierra, J.

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain

ClinicoEconomics and Outcomes Research. 2021; 13: 263-277 Nº de citas: 6 [doi:10.2147/CEOR.S302097]